Ibuprofen Tablets — Competitive Intelligence Brief

Ibuprofen Tablets (Ibuprofen Tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management, Inflammation, Rheumatology.

marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2 Pain Management, Inflammation, Rheumatology Small molecule

Target snapshot

Ibuprofen Tablets (Ibuprofen Tablets) — Overseas Pharmaceuticals, Ltd.. Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce the production of prostaglandins, thereby decreasing inflammation, pain, and fever.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ibuprofen Tablets TARGET	Ibuprofen Tablets	Overseas Pharmaceuticals, Ltd.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Metamizole Sodium	Metamizole Sodium	Insel Gruppe AG, University Hospital Bern	marketed	Non-steroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Phenylephrine 1.0%/ Ketorolac 0.3%	Phenylephrine 1.0%/ Ketorolac 0.3%	University of Florida	marketed	Combination ophthalmic decongestant and NSAID	Alpha-1 adrenergic receptor (phenylephrine); COX-1 and COX-2 (ketorolac)
Ketorolac Tromethamine 0.45%	Ketorolac Tromethamine 0.45%	Bucci Laser Vision Institute	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Bromfenac 0.09 % Ophthalmic Solution	Bromfenac 0.09 % Ophthalmic Solution	Azienda USL Reggio Emilia - IRCCS	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
ketorolac tromethamine 0.4%	ketorolac tromethamine 0.4%	Clinica Oftamologica Zona Sul	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class